
|Videos|May 2, 2015
CHECKMATE-069: Spectacular Results With Combination Therapy
Advertisement
Advertisement
Related to this article

VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.

EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.

The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.

The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.

Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.

IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
3
Galinpepimut-S Improves OS in AML in Second or Later Remission
4
ESMO 2026 Data Highlight ADC Activity in Brain Metastases and TNBC
5



